Compare LEE & SGHT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | LEE | SGHT |
|---|---|---|
| Founded | 1890 | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Newspapers/Magazines | Medical Specialities |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 160.1M | 187.4M |
| IPO Year | 2025 | 2021 |
| Metric | LEE | SGHT |
|---|---|---|
| Price | $8.72 | $4.35 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 7 |
| Target Price | N/A | ★ $9.08 |
| AVG Volume (30 Days) | 34.3K | ★ 235.6K |
| Earning Date | 05-07-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 28.16 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $543,955,000.00 | $77,363,000.00 |
| Revenue This Year | $5.48 | $11.67 |
| Revenue Next Year | N/A | $10.39 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $3.34 | $2.74 |
| 52 Week High | $9.97 | $9.24 |
| Indicator | LEE | SGHT |
|---|---|---|
| Relative Strength Index (RSI) | 57.35 | 58.71 |
| Support Level | $8.07 | $3.30 |
| Resistance Level | $9.40 | $5.32 |
| Average True Range (ATR) | 0.47 | 0.20 |
| MACD | 0.00 | 0.14 |
| Stochastic Oscillator | 83.50 | 87.18 |
Lee Enterprises Inc is a local news publication company in the United States. It is a digital-first subscription business providing local markets with valuable, high-quality, trusted, intensely local news, information, advertising, and marketing services. The product portfolio of the company includes digital subscription platforms, daily, weekly, and monthly newspapers, and niche products, all delivering original local news and information as well as national and international news. The products offer digital and print editions, and content and advertising are available in real-time through the websites and mobile apps.
Sight Sciences Inc is an ophthalmic medical device company focused on the development and commercialization of surgical and nonsurgical technologies for the treatment of prevalent eye diseases. The company operates through two segments: Interventional Glaucoma, which generates the majority of revenue and includes the OMNI Surgical System family of products and the SION Surgical Instrument used in minimally invasive glaucoma surgery to reduce intraocular pressure in adult patients with open-angle glaucoma; and Interventional Dry Eye, which includes the TearCare System, an interventional device designed to melt and facilitate the removal of meibomian gland obstructions and restore gland functionality in adult patients with evaporative dry eye disease.